A physical map of the human genomeMutations in the let-7 binding site - a mechanism of RAS activation in juvenile myelomonocytic leukemia?Polymorphisms of methylenetetrahydrofolate reductase (MTHFR) and susceptibility to pediatric acute lymphoblastic leukemia in a German study population.Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.Prognostic impact of WT1 mutations in cytogenetically normal acute myeloid leukemia: a study of the German-Austrian AML Study Group.Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor.Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia.IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis.RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group.Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG).On metabolic reprogramming and tumor biology: A comprehensive survey of metabolism in breast cancerMorphologic dysplasia in de novo acute myeloid leukemia (AML) is related to unfavorable cytogenetics but has no independent prognostic relevance under the conditions of intensive induction therapy: results of a multiparameter analysis from the GermaThe t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2Monitoring CSF proteome alterations in amyotrophic lateral sclerosis: obstacles and perspectives in translating a novel marker panel to the clinicParthenogenetic stem cells for tissue-engineered heart repair.Mass spectrometry for the detection of differentially expressed proteins: a comparison of surface-enhanced laser desorption/ionization and capillary electrophoresis/mass spectrometry.Women's experiences of undergoing BRCA1 and BRCA2 testing: organisation of the German Hereditary Breast and Ovarian Cancer Consortium Survey and Preliminary Data from Münster.Exonuclease-1 deletion impairs DNA damage signaling and prolongs lifespan of telomere-dysfunctional mice.The differentiation/retrodifferentiation program of human U937 leukemia cells is accompanied by changes of VCP/p97Gene therapy for Wiskott-Aldrich syndrome--long-term efficacy and genotoxicity.Prognostic factors in adult patients up to 60 years old with acute myeloid leukemia and translocations of chromosome band 11q23: individual patient data-based meta-analysis of the German Acute Myeloid Leukemia Intergroup.RUNX1 deficiency (familial platelet disorder with predisposition to myeloid leukemia, FPDMM).Analysis of array-CGH data using the R and Bioconductor software suite.Mitotic recombination and compound-heterozygous mutations are predominant NF1-inactivating mechanisms in children with juvenile myelomonocytic leukemia and neurofibromatosis type 1.Radiation rescue: mesenchymal stromal cells protect from lethal irradiation.Constitutional mismatch repair deficiency and childhood leukemia/lymphoma--report on a novel biallelic MSH6 mutationProteomic bronchiolitis obliterans syndrome risk monitoring in lung transplant recipients.Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease.Breast cancer susceptibility: current knowledge and implications for genetic counsellingSNP array analysis of acute promyelocytic leukemia may be of prognostic relevance and identifies a potential high risk group with recurrent deletions on chromosomal subband 1q31.3.Histone deacetylases activate hepatocyte growth factor signaling by repressing microRNA-449 in hepatocellular carcinoma cells.Clinical utility gene card for: Lynch syndrome (MLH1, MSH2, MSH6, PMS2)Cytogenetic characterization of a BCR-ABL transduced mouse cell line.Outcomes in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the MDS-004 study.MN1 overexpression induces acute myeloid leukemia in mice and predicts ATRA resistance in patients with AML.Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia.FLT3-internal tandem duplication and age are the major prognostic factors in patients with relapsed acute myeloid leukemia with normal karyotypeSignificant inverse correlation of microRNA-150/MYB and microRNA-222/p27 in myelodysplastic syndrome.Lenalidomide in the context of complex karyotype or interrupted treatment: case reviews of del(5q)MDS patients with unexpected responses.Haploinsufficiency of ETV6 and CDKN1B in patients with acute myeloid leukemia and complex karyotype
P50
Q22122382-1720C83E-2F13-4DE2-A7BF-FFB6FC1DBB9BQ24620478-E1ADCF2A-1961-4A3E-A961-C764E50E76CBQ24814207-D22EEA4F-3864-4B4A-9EDF-31A502AEF337Q27851430-C6DF195B-3663-4DF6-8EFC-06CDDD0D7E79Q27851464-7577889F-A041-4C72-8998-EAFB78F8F309Q27851558-3E757001-7D89-4880-A4D8-E48B754D2489Q27851562-F4E959A0-492D-4629-9DEF-63267B22A6A9Q27851565-0CDA2CF5-7EA8-40C3-98B8-E1ED97C6C5D9Q27851623-60C20FF6-5ABE-4E17-8CB3-BDAA1612A113Q27852247-C8751211-30AC-4F1F-B976-9535D23CB5B6Q28072798-AE048B9E-3645-415F-B8D0-BEFBEA8B267BQ28202843-66A7E031-3784-4043-836D-553E616963CEQ28243103-827E7A5D-67D8-4A96-9410-4D88715E4DF0Q28483618-A2452193-372F-4B14-A0D8-2E787D764B56Q30536576-A2276864-F449-474D-830D-EDD0C91BACF4Q31038387-A3084832-4640-4362-820C-DC1833230A26Q33206254-721CB399-645F-4342-BFCC-A61CC7527066Q33297433-F1DCBCC7-EB2A-4FC2-A870-BAF3C1358BC6Q33320073-33EC1275-6812-46B0-A288-2DC876A8CF45Q33413888-BCD54371-9253-426A-BE4C-92313900AAEFQ33432481-19A7AEDD-2853-4FA1-8F2B-74B1A3722978Q33442883-FCE4B8DC-1720-4CAE-9193-62F8BC7D64EDQ33495596-CDFCF46F-2729-4D78-99D7-EC1300352208Q33632274-B56F5F47-EE4A-4C43-A99C-AF1EFB859D7EQ33796581-5ED2076B-ED5B-4559-80C5-2736CA2168F0Q33829127-6D7F1527-D8DF-45CB-BFF8-304903CEC7CAQ33946296-D3114FE8-8CB6-4B82-858F-96E78B016009Q34094502-6F1D6401-BC18-4B7A-B20C-E74428A28220Q34161642-A8AD41BB-8731-4B7C-AFA4-2A8DD8B11E22Q34226368-F0EE511D-77CA-456B-90FF-168B3A3FD19BQ34277757-D4DECF2D-F030-44C8-AA0A-0B6648D957EEQ34329565-7C7C853F-4444-40EB-B8BE-8001F9D68C37Q34440356-A533A526-24FF-4CF8-8B57-912BC60BA332Q34516294-E91ADF78-F88E-4B2E-9652-7E309899AEF6Q34627288-06371670-912F-490D-A000-6A215EF26D23Q34630212-66A95D75-E316-4C87-83CC-65514C18151FQ34890418-4F5D4F4A-A394-42A8-8718-8EE7FBD7F8C9Q34992853-51598803-5D3C-421F-B7DA-04B02A1E5254Q35230041-B239FBED-3289-4776-8434-4EBB925082BBQ35249211-F3FB8241-F645-4FF4-A050-23A52FFE3A08
P50
description
Duits hooglerares
@nl
German university professor
@en
deutsche Humangenetikerin und Hochschullehrerin
@de
ollamh Gearmánach
@ga
profesora universitaria alemana
@ast
profesora universitaria alemana
@es
profesora universitaria alemá
@gl
professeure d'université allemande
@fr
professora d'universitat alemanya
@ca
professora universitária alemã
@pt
name
Brigitte Schlegelberger
@ast
Brigitte Schlegelberger
@ca
Brigitte Schlegelberger
@da
Brigitte Schlegelberger
@de
Brigitte Schlegelberger
@en
Brigitte Schlegelberger
@es
Brigitte Schlegelberger
@fr
Brigitte Schlegelberger
@it
Brigitte Schlegelberger
@nb
Brigitte Schlegelberger
@nds
type
label
Brigitte Schlegelberger
@ast
Brigitte Schlegelberger
@ca
Brigitte Schlegelberger
@da
Brigitte Schlegelberger
@de
Brigitte Schlegelberger
@en
Brigitte Schlegelberger
@es
Brigitte Schlegelberger
@fr
Brigitte Schlegelberger
@it
Brigitte Schlegelberger
@nb
Brigitte Schlegelberger
@nds
prefLabel
Brigitte Schlegelberger
@ast
Brigitte Schlegelberger
@ca
Brigitte Schlegelberger
@da
Brigitte Schlegelberger
@de
Brigitte Schlegelberger
@en
Brigitte Schlegelberger
@es
Brigitte Schlegelberger
@fr
Brigitte Schlegelberger
@it
Brigitte Schlegelberger
@nb
Brigitte Schlegelberger
@nds
P214
P227
P106
P1412
P1559
Brigitte Schlegelberger
@de
P19
P2080
P21
P213
0000 0000 2005 4031
P214
P227
P31
P569
1956-09-22T00:00:00Z
P735
P7859
viaf-77510123